The DOI matches its Crossref record.
Poor outcome in steroid-refractory graft-versus-host disease with antithymocyte globulin treatment
Open accessAbstract
Treatment of acute graft-versus-host disease (aGVHD) has relied on high-dose steroids, but less than 50% of patients show durable remission. Antithymocyte globulin (ATG) has become a standard salvage therapy. We now report our experience with ATG for the treatment of steroid-refractory GVHD in 69 patients treated from January 1, 1980, to May 1, 1999. Patients with GVHD were given an overall grade using standard criteria. Overall responses were similar to those in previously published literature. However, long-term survival for this group of patients was dismal. Of the 69 patients treated with ATG for steroid-refractory GVHD, only 3 (5%) are currently alive. The median survival of these patients by GVHD grade was 4.1 months for grade 2, 3.6 months for grade 3, and 2.7 months for grade 4. The age range of the surviving patients was 3 to 25 years. Only 5% of the deaths were due to relapse, with the remaining deaths due to GVHD, infection, and/or organ failure. In conclusion, ATG treatment can produce objective responses in patients with aGVHD, but these responses do not result in long-term survival. Given the poor survival rates of patients treated with ATG for steroid-refractory GVHD, treatment with ATG as standard therapy should be reconsidered. Patients with steroid-refractory GVHD should be enrolled in clinical study until there are data to support a standard salvage therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Ferrara, J. L., Levine, J. E., Reddy, P., & Holler, E. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60237-3 · Cited by 2,464
Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease
Zeiser, R., von Bubnoff, N., Butler, J., Mohty, M., Niederwieser, D., Or, R., Szer, J., Wagner, E. M., Zuckerman, T., Mahuzier, B., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1917635 · Cited by 881
Zeiser, R., Burchert, A., Lengerke, C., Verbeek, M., Maas-Bauer, K., Metzelder, S. K., Spoerl, S., Ditschkowski, M., Ecsedi, M., Sockel, K., et al. (2015) · Leukemia · doi:10.1038/leu.2015.212 · Cited by 539
Diagnosis and management of acute graft‐versus‐host disease
Dignan, F. L., Clark, A., Amrolia, P., Cornish, J., Jackson, G., Mahendra, P., Scarisbrick, J. J., Taylor, P. C., Hadzic, N., Shaw, B. E., et al. (2012) · British Journal of Haematology · doi:10.1111/j.1365-2141.2012.09129.x · Cited by 314
A prognostic score for acute graft-versus-host disease based on biomarkers: a multicentre study
Levine, J. E., Braun, T. M., Harris, A. C., Holler, E., Taylor, A., Miller, H., Magenau, J., Weisdorf, D. J., Ho, V. T., Bolaños-Meade, J., et al. (2015) · The Lancet Haematology · doi:10.1016/s2352-3026(14)00035-0 · Cited by 309
Metadata
- Authors
- Arai, S., Margolis, J., Zahurak, M., Anders, V., & Vogelsang, G. B.
- Venue
- Biology of Blood and Marrow Transplantation
- Publisher
- Elsevier BV
- Published
- 2002-03
- Volume
- 8
- Issue
- 3
- Pages
- 155-160
- ISSN
- 1083-8791 (ISSN-L)
- OpenAlex
- W2056328782
- Cited by
- 159
- References
- 0
- FWCI
- 2.89
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Poor outcome in steroid-refractory graft-versus-host disease with antithymocyte globulin treatment. https://app.cochat.ai/papers/10.1053/bbmt.2002.v8.pm11939605
- The paper
- Arai, S., Margolis, J., Zahurak, M., Anders, V., & Vogelsang, G. B. (2002). Poor outcome in steroid-refractory graft-versus-host disease with antithymocyte globulin treatment. Biology of Blood and Marrow Transplantation. https://doi.org/10.1053/bbmt.2002.v8.pm11939605
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.